3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Interventions
Docetaxel
5
Magnetic Resonance Spectroscopy
3
Fluorodeoxyglucose F18
3
ulixertinib
2
X-Rays
2
Trastuzumab
2
Radiotherapy
2
Filgrastim
2
FAPI-46
2
Carboplatin
2
vocimagene amiretrorepvec
1
trastuzumab biosimilar HLX02
1
trametinib
1
tovorafenib
1
tipifarnib
1
tanespimycin
1
sapanisertib
1
sacituzumab govitecan
1
romidepsin
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
oblimersen
1
motexafin gadolinium
1
larotrectinib
1
ipatasertib
1
fludarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Molecular Diagnostic Techniques
×
CNS
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled